AstraZeneca entered a new kidney-focused discovery collaboration with CSPC Pharmaceutical, agreeing to pay $30 million upfront and jointly develop two kidney disease drug candidates. The pact is part of AstraZeneca’s continued expansion of external partnering for early discovery programs. The deal centers on identifying and progressing candidates from discovery into development, leveraging CSPC’s platform and AstraZeneca’s global development capabilities. For kidney disease pipelines—where late-stage success can be sparse—adding two pre-defined candidates increases near- and mid-term optionality. Both companies said they will work across discovery and advancement of selected molecules, with further details tied to milestones not included in the provided report. For biotech deal flow, the agreement underscores continued investor and corporate appetite for platform-enabled discovery in hard-to-treat therapeutic areas.